Dr. Andrew Miller is a highly accomplished biopharmaceutical executive with expertise in neuroscience research and development, company building, capital formation, and corporate strategy. Most recently, Dr. Miller was the Founder of and President of Research and Development at Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT (COBENFY™) and previously served as Chief Operating Officer and Chief Executive Officer and as a member of Karuna’s board of directors. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics.
Dr. Miller played a lead role in developing KarXT from the initial idea to the approval of COBENFY™ for the treatment of schizophrenia in 2024, as well as building the company from 1 employee to over 350 and raising ~$2B in private and public investor capital prior to the acquisition of Karuna for $14B in 2024. During his tenure at Karuna, Dr. Miller oversaw clinical development, nonclinical development, regulatory, quality, manufacturing and formulation development, human resources, and corporate development.
Dr. Miller has more than 15 years of experience in the biotech/biopharma industry, previously holding senior and executive level positions at PureTech Health, Tal Medical, and Entrega Inc. Dr. Miller received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology as a Presidential Fellow and a bachelor’s degree in Chemical Engineering from the University of Illinois with the highest honors. Dr. Miller was named to the PharmaVoice 100 and one of the top 40 innovators under 40 by MedTech Boston.
Back to Team